Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

Harrison, CN; Nangalia, J; Boucher, R; Jackson, A; Yap, C; O'Sullivan, J; Fox, S; Ailts, I; Dueck, AC; Geyer, HL; Mesa, RA; Dunn, WG; Nadezhdin, E; Curto-Garcia, N; Green, A; Wilkins, B; Coppell, J; Laurie, J; Garg, M; Ewing, J; Knapper, S; Crowe, J; Chen, F; Koutsavlis, I; Godfrey, A; Arami, S; Drummond, M; Byrne, J; Clark, F; Mead-Harvey, C; Baxter, EJ; McMullin, MF; Mead, AJ

Journal article

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

Abstract:: Purpose
Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.

Patients and Methods
MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response.

Results
One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported.

Conclusion
The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Harrison, C. N., Nangalia, J., Boucher, R., Jackson, A., Yap, C., O'Sullivan, J., Fox, S., Ailts, I., Dueck, A. C., Geyer, H. L., Mesa, R. A., Dunn, W. G., Nadezhdin, E., Curto-Garcia, N., Green, A., Wilkins, B., Coppell, J., Laurie, J., Garg, M., … Mead, A. J. (2023). Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. Journal of Clinical Oncology, 41(19), 3534–3544.

MLA Style

Harrison, CN, et al. “Ruxolitinib versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.” Journal of Clinical Oncology, vol. 41, no. 19, 2023, pp. 3534–44.

Chicago Style

Harrison, CN, J Nangalia, R Boucher, et al. 2023. “Ruxolitinib versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.” Journal of Clinical Oncology 41 (19): 3534–44.
Print